Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 09:57 ET | Source: Trethera Corporation

Trethera Successfully Completes Phase 1 Dose Escalation Trial Demonstrating Broad Therapeutic Window, Favorable Safety, and Confirmed Target Engagement

Achieved complete target inhibition, durable tumor control, and a 36-fold dose range without dose-limiting toxicity— advancing toward combination trials.
September 23, 2025 10:07 ET | Source: Trethera Corporation

Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease

TRE-515, the only dCK inhibitor in development, secures $1.8M NIH grant after outperforming market-leader Stelara in Crohn’s studies.
September 10, 2025 10:11 ET | Source: Trethera Corporation

Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors

Phase 1 enrollment of TRE-515 in solid tumors completed; 36-fold dose escalation well tolerated, with early signs of antitumor activity and durable benefit
August 26, 2025 10:22 ET | Source: Trethera Corporation

Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy in Prostate Cancer Preclinical Models

Fresh NIH funding follows FDA Fast Track designation, reinforcing confidence in TRE-515 potential to advance prostate cancer treatment.
August 19, 2025 09:28 ET | Source: Trethera Corporation

Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus

$3M NIH grant advances TRE-515, a first-in-class lupus therapy. Funding supports safety, biomarker studies, and paves the way for patient trials.
July 30, 2025 09:24 ET | Source: Trethera Corporation

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers

Creates platform for precision dosing, companion diagnostics, streamlined development, and broader use across cancer and autoimmune diseases.
July 09, 2025 09:22 ET | Source: Trethera Corporation

FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer

TRE-515 receives FDA Fast Track for use with Pluvicto™ in advanced prostate cancer, aiming to improve outcomes in PSMA-positive, treatment-resistant cases.
June 03, 2025 09:10 ET | Source: Trethera Corporation

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045

Global exclusive agreement expands patent coverage for compound structures and autoimmune uses across major pharmaceutical markets
May 21, 2025 09:12 ET | Source: Trethera Corporation

Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board

Trethera enlists leading expert in demyelinating diseases to advance TRE-515, a first-in-class drug with FDA Orphan Drug status for ADEM and optic neuritis
April 22, 2025 08:57 ET | Source: Trethera Corporation

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases,...